Amylyx Pharmaceuticals (AMLX) Price to Earnings (2022 - 2026)
Amylyx Pharmaceuticals (AMLX) posted Price to Earnings of 46.12 for Q2 2026, down 23.15% on a QoQ basis from 37.45 in Q1 2026, and down 234.44% year-over-year from 34.3 in Q2 2025.
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) Price to Earnings (2022 - 2026) Analysis & Trends
Amylyx Pharmaceuticals has reported Price to Earnings for 5 years, with the latest figure at 46.12 in Q2 2026.
- On a quarterly basis, Price to Earnings fell 234.44% year-over-year to 46.12 in Q2 2026; TTM through Jun 2026 was 16.46, a 258.66% decrease from a year earlier, with the FY2025 full-year figure at 11.61, down 968.47% from the prior year.
- Price to Earnings was 46.12 for Q2 2026 at Amylyx Pharmaceuticals, down from 37.45 in the prior quarter.
- The five-year high for Price to Earnings was 1251.48 in Q1 2023, with the low at 516.7 in Q4 2025.
- Average Price to Earnings over 5 years is 45.11, with a median of 11.29 recorded in 2025.
- The sharpest annual moves came in 2023 and 2025: Price to Earnings surged 8153.34% in 2023, then plunged 5180.96% in 2025.
- Over 5 years, Price to Earnings stood at 56.11 in 2022, then jumped by 494.13% to 221.13 in 2023, then slumped by 95.4% to 10.17 in 2024, then tumbled by 5180.96% to 516.7 in 2025, then surged by 91.07% to 46.12 in 2026.
- The last three Price to Earnings figures came in at 46.12 (Q2 2026), 37.45 (Q1 2026), and 516.7 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn |
| 10 | Amylyx Pharmaceuticals | 3.69 Bn | 3.69 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -46.12 |
| Mar 31, 2026 | -37.45 |
| Dec 31, 2025 | -516.70 |
| Sep 30, 2025 | -43.38 |
| Jun 30, 2025 | -13.79 |
| Mar 31, 2025 | -8.78 |
| Dec 31, 2024 | 10.17 |
| Sep 30, 2024 | -3.05 |
| Jun 30, 2024 | -1.78 |
| Mar 31, 2024 | -1.63 |
| Dec 31, 2023 | 221.13 |
| Sep 30, 2023 | 59.16 |
| Jun 30, 2023 | 65.82 |
| Mar 31, 2023 | 1,251.48 |
| Dec 31, 2022 | -56.11 |
| Sep 30, 2022 | -30.65 |
| Jun 30, 2022 | -20.84 |
| Mar 31, 2022 | -15.54 |